Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study on the Safety, Tolerability and Pharmacokinetics/-Dynamics of Escalating Single Intravenous Doses of AK1967 (Procizumab) in Healthy Male Volunteers

NCT06331884 is registered in ClinicalTrials.gov with 4TEEN4 Pharmaceuticals GmbH as lead sponsor.

NCT NCT06331884
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06331884 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study on the Safety, Tolerability and Pharmacokinetics/-Dynamics of Escalating Single Intravenous Doses of AK1967 (Procizumab) in Healthy Male Volunteers
Lead sponsor
4TEEN4 Pharmaceuticals GmbH
Phase
Phase 1
Overall status
Completed
Start date
March 7, 2024
Completion date
September 4, 2024
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers, safety and tolerability